Google
ALVO Stock Analysis — ALVOTECH (Healthcare >> Drug Manufacturers - Specialty & Generic)
ALVO FAQ
What is ALVO's P/E ratio?
ALVOTECH (ALVO) currently trades at a P/E ratio of -15.99.
What is ALVO's ROE?
ALVOTECH reports a Return on Equity (ROE) of 28.60%.
What is ALVO's dividend yield?
ALVOTECH offers a dividend yield of 0.00%.
What is ALVO's Quality Score?
Our AI rates ALVO's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ALVO?
Our AI Timing Score for ALVO is 66 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ALVO belong to?
ALVOTECH is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange
ALVO AI Analysis Summary
Our AI summary for ALVO: ALVOTECH (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of -15.99, ROE of 28.60%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 66/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 4.12
Price
0.55
(15.41%)
Day Change
|
|
|---|
ALVO, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.12 |
| PBV / Sector |
-4.28 / 3.22
|
| Earning Per Share | -0.28 |
| PE / Sector |
N/A / 29.79
|
| PEG or PE/Growth / Sector |
0.26 / 0.13
GREAT
|
| Average 1M Daily Value |
2.66 M
GREAT
|
| Average 1W Daily Value |
4.72 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:28 |
| Symbol | ALVO |
| Name | ALVOTECH |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 338.22 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,207.44 / 10,754.62 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 9, Rue de Bitbourg, Luxembourg, Luxembourg, 1273
Phone: 354 422 4500
Website: https://www.alvotech.com
Employees: 1,279
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › Drug Manufacturers - Specialty & GenericAnalysed on the same criteria, ordered by market cap